Publication: 3561

Publication: 3561

A prospective economic analysis of early outcome data from the Alliance A041202/ CCTG CLC.2 randomized phase III trial of bendamustine-rituximab compared with ibrutinib-based regimens in untreated older patients with chronic lymphocytic leukemia

PubMed

PMC

QxMD

DOI

Google Scholar

Citation:: Clin Lymphoma Myeloma Leuk vol 21 (11) 766-774

Year:: 2021
Type:: Manuscript
Funding:: NCTN
Endpoint:: Secondary-not-in-original
Analysis:: Primary
Data Sharing:: Alliance-data-source,-external-user
Status:: Presented/Published
Citation Status:: pmc-release

Note:

Methodological:: No
Biospecimen:: No
SDC:: No
Book Volume:

Parents:: 3396
Children:: None

Program:: OGC
Primary Committee:: Leukemia
Sec. Committees:

Pharmas:: Pharmacyclics, Inc.
Grants:: U10CA180821, U10CA180882, UG1CA233331; U10CA180863, #704970 (CCTG)

Corr. Author:
Authors:: Matthew C. Cheung Nicole Mittmann Carolyn Owen Nizar Abdel-Samad Graeme A. M. Fraser Selay Lam Michael Crump Catherine Sperlich Richard van der Jagt Anca Prica Stephen Couban Jennifer A. Woyach Amy S. Ruppert Allison M. Booth Sumithra J. Mandrekar Gail McDonald Lois E. Shepherd Hope Yen Bingshu E. Chen Annette E. Hay

Networks:: LAPS-MN026, LAPS-OH007

Study: Alliance-A151905
Multiple Studies, or Legacy Studies in Alliance Study:: Alliance-A041202
Phases:: N/A, 3

Keywords:: Economic analysis, chronic lymphocytic leukemia, ibrutinib, bendamustine-rituximab, phase III trial